(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 20.6% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.51%.
Grail's revenue in 2026 is $165,263,000.On average, 11 Wall Street analysts forecast GRAL's revenue for 2026 to be $8,229,306,952, with the lowest GRAL revenue forecast at $7,699,565,417, and the highest GRAL revenue forecast at $8,667,036,045. On average, 11 Wall Street analysts forecast GRAL's revenue for 2027 to be $10,313,433,431, with the lowest GRAL revenue forecast at $9,060,992,229, and the highest GRAL revenue forecast at $11,727,119,737.
In 2028, GRAL is forecast to generate $13,059,513,497 in revenue, with the lowest revenue forecast at $10,374,179,509 and the highest revenue forecast at $16,418,860,956.